Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong
Metrics: PDF 671 views | HTML 1358 views | ?
Chi Yuen Cheung1, Maggie Kam Man Ma2, Ka Foon Chau1, Wai Leung Chak1 and Sydney Chi Wai Tang2
1Renal Unit, Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China
2Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
Sydney Chi Wai Tang, email: firstname.lastname@example.org
Keywords: lymphoma, posttransplant lymphoproliferative disorders, kidney transplant
Received: February 22, 2017 Accepted: June 04, 2017 Published: June 30, 2017
Objective: To characterize the posttransplant lymphoproliferative disorders (PTLD) including the Epstein-Barr virus (EBV) status, histological subgroups, site of occurrence and the clinical outcome in the Chinese kidney transplant recipients.
Methods: A retrospective cohort study of 1, 227 adult kidney transplant recipients who were followed up in two transplant centers in Hong Kong over two decades.
Results: 23 (1.9%) patients developed PTLD. Median duration from transplant to PTLD was 104 (5-252) months. Six patients (26.1%) had early PTLD and 17 (73.9%) had late PTLD. Ten (43%) developed PTLD >10 years after transplant. All patients in early PTLD group were EBV-positive. In the late PTLD group, 60% were EBV-negative and 40% EBV-positive. More than 90% of cases were monomorphic PTLD with majority being diffuse large B cell lymphoma. Bone marrow was the most common extranodal site. The overall treatment response rate was 52.2 %. None of the patients developed rejection or relapse after PTLD. At a median follow-up of 9 (1-79) months after PTLD, 18 patients died. Patient survival was 48% at 1 year and 30% at 3 years and death-censored allograft survival was 82% at 1year and 73% at 3 years.
Conclusion: Late PTLD is common. Careful adjustment of immunosuppression, close monitoring of patients, increased awareness and early detection of the disease are essential.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.